Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca M. Marin, Jann N. Sarkaria, Kendra A. Porath et al.|Neuro-Oncology|2021Cited by 81
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain BarrierMinjee Kim, Jann N. Sarkaria, Karen E. Parrish et al.|Molecular Cancer Therapeutics|2018Cited by 40
Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemiaShulan Tian, Wei Ding|Scientific Reports|2021Cited by 3
Data from Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain BarrierMinjee Kim, Jann N. Sarkaria, J. Daniel et al.|Unknown|2023Cited by 0